Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

Isaac García-Murillas(Breast Cancer Now), Nicholas C. Turner(Institute of Cancer Research), Maria Afentakis(Breast Cancer Now), Abigail Evans(Poole Hospital), Holly Tovey(Institute of Cancer Research), Duncan Wheatley(National Health Service), Stephen Johnston(Royal Marsden NHS Foundation Trust), Divya Kriplani(Institute of Cancer Research), Peter Barry(Royal Marsden Hospital), Rosalind Cutts(Breast Cancer Now), Sarah Hrebien(Breast Cancer Now), Mitch Dowsett(Institute of Cancer Research), Matthew Beaney(Breast Cancer Now), Simon Russell(Hinchingbrooke Hospital), Claire Swift(Institute of Cancer Research), Giselle Walsh-Crestani(Breast Cancer Now), Iñaki Comino‐Méndez(Breast Cancer Now), Neha Chopra(Schrodinger (United States)), Ian E. Smith(Papworth Hospital), Judith M. Bliss(Institute of Cancer Research), Anthony Skene(Royal Bournemouth Hospital), Alistair Ring(National Health Service)
JAMA Oncology
August 1, 2019
10.1001/jamaoncol.2019.1838
Cited by 425

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k